3980 PREMIER DR, HIGH POINT, NC
vTv Therapeutics Inc. Increases Class A Common Stock Offering Under ATM Program
Financial Results, Press Release
Investor Presentation
vTv Therapeutics Enters Second Amendment with Newsoara for PDE4 Inhibitor
vTv Therapeutics Inc. Amends By-Laws to Change Quorum Requirement
Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Reg. FD
Q1
FY 2025
Q3
Q2
FY 2024
Registration Statement for Securities to be Offered to Employees
Prospectus Filed Pursuant to Rule 424(b)(2)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
Definitive Information Statement
Preliminary Information Statement
Additional Proxy Materials
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Amended Schedule 13D - Ownership Report
Correspondence
Submission Upload
Confidential Treatment Order